"Non-invasive Pneumococcal Diseases dynamics & the Host Age" Roman Prymula Ministry of Health, the Czech Republic
|
|
- Hector James
- 5 years ago
- Views:
Transcription
1 "Non-invasive Pneumococcal Diseases dynamics & the Host Age" Roman Prymula Ministry of Health, the Czech Republic
2 Disease Caused by S. pneumoniae S. pneumoniae Eustachian Tube Nasopharynx Pharynx Nasal Cavity Trachea Larynx Primary Bronchi Lungs Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
3 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Eustachian Tube Nasopharynx Pharynx Nasal Cavity Trachea Larynx Primary Bronchi Lungs Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
4 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Upper Respiratory Tract Infections Sinusitis Otitis media Eustachian Tube Nasopharynx Pharynx Nasal Cavity Trachea Larynx Primary Bronchi Lungs Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
5 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Upper Respiratory Tract Infections Sinusitis Otitis media Eustachian Tube Nasopharynx Pharynx Nasal Cavity Trachea Larynx Lower Respiratory Tract Infections Pneumonia Primary Bronchi Lungs Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
6 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Meningitis Upper Respiratory Tract Infections Sinusitis Otitis media Eustachian Tube Nasopharynx Pharynx Nasal Cavity Invasive Diseases Trachea Larynx Lower Respiratory Tract Infections Pneumonia Primary Bronchi Bacteraemia/ Sepsis Lungs Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
7 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Meningitis Upper Respiratory Tract Infections Sinusitis Otitis media Treatment with antibiotics Trachea Eustachian Tube Nasopharynx Pharynx Larynx Nasal Cavity Invasive Diseases Lower Respiratory Tract Infections Pneumonia Primary Bronchi Lungs Bacteraemia/ Sepsis Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
8 Disease Caused by S. pneumoniae S. pneumoniae Bacterial respiratory pathogens Meningitis Upper Respiratory Tract Infections Sinusitis Otitis media Treatment with antibiotics Trachea Nasal Cavity Eustachian Tube Nasopharynx Pharynx Antibiotics Larynx resistance! Invasive Diseases Lower Respiratory Tract Infections Pneumonia Primary Bronchi Lungs Bacteraemia/ Sepsis Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, et al, eds. 11th ed. Washington DC: Public Health Foundation, Chapter 15: Pneumococcal Disease. Dagan R, Klugman KP. Chapter 25: Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. In: Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Siber G, et al (eds). ASM Press, Washington DC (2008). pp374.
9 High burden childhood pneumococcal disease has driven the search for adequate paediatric vaccines Vaccination drivers Meningitis Bacteraemia Pneumonia Severity Deaths Transmission Hospitalization Cost Non-invasive diseases (Otitis media) Volume of cases Cost ATB use & resist. CDC MMWR 1997 & 2000; Dagan R, Textbook of Pediatric Infectious Diseases. 5th ed.; 2004 ; Melegaro J. Infection 2006; Ziebold Acta Pædiatr 2000; Valenzuela MT PAHO J. 2007; Leimkugel J Infect Dis 2005; NTHi: non-typeable Haemophilus influenzae
10 High burden childhood pneumococcal disease has driven the search for adequate paediatric vaccines CDC MMWR 1997 & 2000; Dagan R, Textbook of Pediatric Infectious Diseases. 5th ed.; 2004 ; Melegaro J. Infection 2006; Ziebold Acta Pædiatr 2000; Valenzuela MT PAHO J. 2007; Leimkugel J Infect Dis 2005; NTHi: non-typeable Haemophilus influenzae
11 Non-invasive pneumococcal diseases These may be less serious than invasive pneumococcal disease and occur outside the major organs or the blood. S. pneumoniae can spread from the nasopharynx (nose and throat) to the upper and lower respiratory tract and can cause: Otitis media - middle ear infection. Inflammation of the middle ear, typically with accumulation of fluid in the middle ear, swelling of the eardrum, earache. If the eardrum is perforated drainage of pus into the ear canal. Streptococcus pneumoniae conjunctivitis is a characteristically acute and painless infection with occasional pruritus. On inspection, the conjunctiva is thickened and injected and there is purulent, sometimes profuse, discharge. The infection is often self-limiting but topical antibiotic treatment may be required. Non-bacteremic pneumonia - infection of the lower respiratory tract without detectable spread of organisms to the blood stream CDC, ECDC, 2018
12 Colonization and Carrier State I Torres, A. CAI, 2014
13 Colonization and Carrier State II Torres, A. CAI, 2014
14 Carriage prevalence and serotype distribution of Streptococcus pneumoniae prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, Neckars F., et al. Vaccine 2017.
15 Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Open, controlled, not randomized trial in Czech Republic PHiD-CV + DTPa-HBV-IPV/Hib + HRV* (N=414) with or without prophylactic paracetamol (PP) Dose 1 3 months of age Dose 2 4 months of age Dose 3 5 months of age Booster months of age *HRV only co-administered with the 1 st and 2 nd PHiD-CV dose Prymula et al. Lancet 2009; 374: ; Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113); Prymula et al. ISPPD-7 Tel Aviv, March 2010 (Abstract 530)
16 Swab Swab Swab Swab Swab Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Open, controlled, not randomized trial in Czech Republic PHiD-CV + DTPa-HBV-IPV/Hib + HRV* (N=414) with or without prophylactic paracetamol (PP) MenACWY-TT control + DTPa-HBV-IPV/Hib (N=336) Dose 1 3 months of age Dose 2 4 months of age Dose 3 5 months of age Booster months of age *HRV only co-administered with the 1 st and 2 nd PHiD-CV dose Prymula et al. Lancet 2009; 374: ; Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113); Prymula et al. ISPPD-7 Tel Aviv, March 2010 (Abstract 530) Months post-vaccination
17 % colonization 20 Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Booster dose Pneumococcal vaccine serotypes (VT) % (ns) -34%* -22% (ns) -31% (ns) -35%* 5 Control Synflorix Study Month M0 M1 M3 M7 M12 Age (months) Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113) * statistically significant difference based on non-overlapping 95% confidence intervals; ns = not statistically significant
18 % colonization 20 Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Booster dose Pneumococcal vaccine serotypes (VT) Synflorix with PP Control Synflorix without PP Study Month M0 M1 M3 M7 M12 Age (months) Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113)
19 % colonization Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Pneumococcal non-vaccine serotypes (NVT), non-cross-reactive 20 serotypes Booster dose % (ns) +14% (ns) +19% (ns) +45% (ns) 5-16% (ns) Control Synflorix Study Month M0 M1 M3 M7 M12 Age (months) Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113) ns=not statistically significant
20 % colonization Effect of PHiD-CV on pneumococcal nasopharyngeal carriage Pneumococcal non-vaccine serotypes (NVT), non-cross-reactive 20 serotypes Booster dose Synflorix with PP Control Synflorix without PP Study Month M0 M1 M3 M7 M12 Age (months) Prymula et al. WSPID Buenos Aires, Nov 2009 (Abstract 1113)
21 Impact of the 13-valent Pneumococcal Conjugate Vaccine on Chronic Sinusitis Associated With Streptococcus pneumoniae in Children (Texas, Houston) Olarte Liset, PIDJ, 2014 Despite effectiveness of pneumococcal conjugate vaccines, Streptococcus pneumoniae is still an important pathogen in chronic sinusitis among children younger than 5 years. Overall, - 14% of participants had a positive sinus culture for S. pneumoniae; - 22% were in the pre-vaccine period - 9% were in the post-vaccine period (P<.0001). Year Cases Chronic nasal congestion/drainage and chronic cough were present in all patients. Before surgery, information on antibiotic therapy was available in 43 patients and 40 had received an antibiotic within 4 weeks before surgery. Chronic otitis media (67%) was the most common comorbid condition, followed by allergic rhinitis (37%), reactive airway disease/asthma (30%) and gastroesophageal reflux (15%).
22 The complexity of acute otitis media Bacterial pathogen(s) C. Deriez
23 The complexity of acute otitis media Bacterial pathogen(s) AOM (Acute Otitis Media) C. Deriez
24 The complexity of acute otitis media Bacterial pathogen(s) AOM (Acute Otitis Media) or watchful waiting C. Deriez
25 The complexity of acute otitis media Bacterial pathogen(s) AOM (Acute Otitis Media) or watchful waiting OME (Otitis Media with Effusion) C. Deriez
26 The complexity of acute otitis media Bacterial pathogen(s) AOM (Acute Otitis Media) or watchful waiting Rare, severe complications (Mastoiditis, meningitis) OME (Otitis Media with Effusion) C. Deriez
27 The complexity of acute otitis media Bacterial pathogen(s) RECURRENT AOM AOM (Acute Otitis Media) SURGERY (Tympanostomy tubes) or watchful waiting Rare, severe complications (Mastoiditis, meningitis) OME (Otitis Media with Effusion) OME (hearing, learning disability) C. Deriez
28 The Otitis Media Spectrum Recurrence and persistence are the hallmarks of OM 1,2 Terms Acute OM (AOM) Initial AOM episode Recurrent OM (ROM) 3 episodes in 6 months or 4 episodes in 12 months 3 Chronic OM (COM) 6 episodes in 6 months Chronic Suppurative OM (CSOM) COM or chronic OME with perforation OM spectrum Symptoms Pain, fever 4 Draining ears OM with effusion (OME) 5 Tympanic perforation OM with tympanic perforation Chronic perforation Suppurative complications 1 Mastoiditis, hearing loss, brain abscess, meningitis 1. Available at. (accessed Nov 2007) 2. Teele DW, et al. J Infect Dis 1989;160: Pichichero ME. Pediatr Infect Dis J 2000;19: Kenna M. Otitis media and its complications. In: Behrmann RE et al, editors. Nelson Textbook of Pediatrics 16th ed. Philadelphia, PA: W.B Saunders p Daly KA, et al. Pediatr Rev 1999;20:85 93.
29 29 POET Study Design Czech and Slovak Republics Double blind, randomized (1:1) study Protein D conjugate vaccine prototype 11 Pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F* 1 µg of every serotype conjugated individually to protein D Control vaccine Hepatitis A vaccine (Havrix TM -720 ELISA units) of inactivated virus antigen Three doses at 3, 4 and 5 months* + booster at months Concomitant EPI vaccine DTPa-HBV-Hib/IPV (Infanrix hexa TM ) administered in both groups at 3.4 and 5 months of age. Booster followed at months of age ~ infants, with 24 months follow-up m Prymula R, et al. Lancet 2006;367:
30 30 Vaccine efficacy (VE)- Bacterial AOM Total = No of bacterial AOM V-Pn serotypes+crossr serotypes Non-vaccine Pn serotypes H. influenzae M. catarrhalis 36 Control group (N=2452) Prymula R, et al. Lancet 2006;367: Vaccine group (N=2455) Others
31 31 Vaccine efficacy (VE)- Bacterial AOM Total = VE against bacterial AOM = 42% No of bacterial AOM 25 VE = 58% 68 V-Pn serotypes+crossr serotypes Non-vaccine Pn serotypes Control group (N=2452) Prymula R, et al. Lancet 2006;367: VE = 36% Vaccine group (N=2455) H. influenzae M. catarrhalis Others
32 32 Serotype Specific Efficacy Control 11Pn-PD (N=2452) (N=2455) VE (%) 95%CI Clinical B V C F F F Any VT A A NTHi Prymula et al. Lancet 2006;367:740-8
33 No protection against serotype 3 AOM in POET: why? Polysaccharide capsules known to protect bacteria against immune system Serotype 3 pneumococci are abundantly capsulated Polysaccharide capsule Hammerschmidt et al. IAI 2005; 73:4653 Serotype 3 Serotype 19F
34 Seasonality of AOM cases in the US, /8/ Tong S., et al. BMC Health Serv Res
35 Community-acquired pneumonia (CAP) Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside of hospital or healthcare facilities. Clinical diagnosis is based on a group of signs and symptoms related to lower respiratory tract infection with presence of fever >100ºF (>38ºC), cough, expectoration, chest pain, dyspnea, and signs of invasion of the alveolar space. However, older patients in particular are often afebrile and may present with confusion and worsening of underlying diseases. Is one of the most common infectious diseases and is an important cause of mortality and morbidity worldwide. Typical bacterial pathogens that cause CAP include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis The most common viral pathogens recovered from hospitalized patients admitted with CAP include human rhinovirus and influenza.
36 Woodhad, 1998
37 Study CAPITA (Community-Acquired Pneumonia Immunization Trial in Adults) Netherland healthy volunteers Age 65 let Prevenar 13 vs. Placebo Primary objective: Efficacy of PCV13 in prevention of the first CAP (community-acquired pneumonia) episode caused by vaccine serotypes Secondary objectives: Efficacy of PCV13 in prevention of the first non-bacteremic (noninvasive) episode caused by vaccine serotypes Efficacy of PCV13 in prevention of the first IPO episode caused by vaccine serotypes Hak E, Grobbee DE, Sanders EAM, et al. Netherlands J Med. 2008;66:
38 Microbiological Definitions for Primary and Secondary Endpoints Endpoint Definition Confirmed VT pneumococcal CAP Confirmed NB/NI VT pneumococcal CAP (1) Presence of 2 or more specified clinical findings consistent with CAP AND (2) Chest x-ray consistent with CAP AND (3) Culture of VT S pneumoniae from blood, pleural fluid or other sterile site and/or positive VT SSUAD Confirmed VT pneumococcal CAP for which a blood culture result is available and is negative and for which any other culture results from pleural fluid or other sterile site are negative for S pneumoniae VT-IPD VT S pneumoniae in blood, pleural fluid or other sterile site, If no serotype was determined from the S pneumoniae culture isolate and a serotype was determined by SSUAD for the same case, the SSUAD serotype was assigned to the case. Bonten, N
39 60 1st Episode VT-CAP Cumulative Case Counts 30 1st Episode VT-IPD Days since vaccination Days since vaccination 60 1st Episode NB/NI VT- CAP Days since vaccination Days since vaccination plots from post hoc analysis 39
40 60 1st Episode VT-CAP Cumulative Case Counts 30 1st Episode VT-IPD Days since vaccination Days since vaccination 60 1st Episode NB/NI VT- CAP Interim analyses (1 st episode VT-CAP, n=74) PCV13 Placebo VE 99.48% CI p-value , Final analyses (1 st episode VT-CAP, n=139) 95.2% CI , Days since vaccination Days since vaccination plots from post hoc analysis 40
41 Study CAPITA (Community-Acquired Pneumonia Immunization Trial in Adults) Study confirmed both primary and secondary objectives efficacy against community pneumonia and IPO in persons 65 years and older Objective Prevenar 13 (n=42,240) Placebo (n=42,256) VE (%) 95.2% CI P-value First CAP episode caused by vaccine serotypes (21.82,62.49) First non-bacteremic (noninvasive) episode caused by vaccine serotypes (14.21, 65.31) First IPO episode caused by vaccine serotypes (41.43, 90.78)* Presented at ISPPD-9, March 9-14, 2014, Hyderabad, India * 95% CI
42 Serotype Distribution 42
43 Serotype Distribution 43
44 Serotype Distribution 44
45 Figure 1. Serotype distribution of the isolates causing non-invasive pneumococcal pneumonia in adults in Portugal ( ). Horácio AN, Lopes JP, Ramirez M, Melo-Cristino J, for the Portuguese Group for the Study of Streptococcal Infections (2014) Non-Invasive Pneumococcal Pneumonia in Portugal Serotype Distribution and Antimicrobial Resistance. PLOS ONE 9(7): e
46 Figure 2. Proportion of isolates expressing serotypes included in pneumococcal vaccines causing noninvasive pneumococcal pneumonia in adults in Portugal ( ). Horácio AN, Lopes JP, Ramirez M, Melo-Cristino J, for the Portuguese Group for the Study of Streptococcal Infections (2014) Non-Invasive Pneumococcal Pneumonia in Portugal Serotype Distribution and Antimicrobial Resistance. PLOS ONE 9(7): e
47 VT serotypes in pneumococcal CAP, UK Chalmers, BMC Pulm Dis, 2016
48 Take home message The most recent available data suggests that VT pneumococcal disease continues to have a high burden in UK adults despite the impact of childhood PCV13. vaccination. IPD estimates represent only a fraction of the total burden of pneumococcal disease. Universal problem: underestimation of non-ipds. Different risk based on age. Chalmers, BMC Pulm Dis, 2016
Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine
Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine Dr. Bernard Hoet Director, Medical affairs GlaxoSmithKline Biologicals Rixensart, Belgium Istanbul, Feb 13, 2008 PHiD-CV: A novel concept in Bacterial
More informationGSK Vaccine Development
GSK Vaccine Development Innovation and new technology to provide a solution Sub-regional Symposium on Pneumococcal in the Caribbean Dominican Republic, Oct 1-2 nd, 2008 Alejandro Lepetic, MD Medical Affairs
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationUPPER RESPIRATORY TRACT INFECTIONS. IAP UG Teaching slides
UPPER RESPIRATORY TRACT INFECTIONS 1 INTRODUCTION Most common problem in children below 5 years. In this age group they get about 6 8 episodes per year. It includes infections of nasal cavity, throat,
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Otitis Media
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Otitis Media Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in
More informationSYNFLORIX TM. adsorbed on aluminium phosphate 0.5 milligram Al conjugated to protein D (derived from NTHi) carrier protein 9-16 micrograms 3
1. NAME OF THE MEDICINAL PRODUCT SYNFLORIX TM Synflorix TM suspension for injection Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)
More informationPotential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada
CPHA 2010 Potential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada Afisi S. Ismaila a,b, Jennifer A. Pereira c, Reid C. Robson a, Gerhart Knerer d a Medical
More informationDefinition. Otitis Media with effusion (OME)
Otitis Media. 1 Dr,wegdan saeed ALFHAL 2 Definition Acute Otitis Media (AOM) acute onset of symptoms, evidence of a middle ear effusion, and signs or symptoms of middle ear inflammation. Otitis Media with
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationReview Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
International Journal of Otolaryngology Volume 2012, Article ID 312935, 15 pages doi:10.1155/2012/312935 Review Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
More informationCost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar
CPHA 2009 Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar Ismaila AS 1,2, Pereira JA 1, Robson RC 1, Rawson NS 1, Simpson SD 1, Standaert BA 3
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationEfficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media
Efficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media Terhi Kilpi National Public Health Institute Department of Vaccines 3rd Regional Pneumococcal Symposium 13 Feb 2008 Incidence of AOM
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More information2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety
2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety Prepared as part of a Ministry of Health contract for services by the Immunisation
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRespiratory Problems in Children
Respiratory Problems in Children A/Prof Alex Tang all that glitters is not gold, all the wheezes is not asthma Objective Describe an overview of respiratory problems in children Define common respiratory
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory SYNFLORIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory SYNFLORIX Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) Ph. Eur. 1. NAME OF THE MEDICINAL PRODUCT Pneumococcal
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Synflorix suspension for injection Synflorix suspension for injection
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationFull public health impact or. cherry-picking?
Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More informationSynflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed
Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram
More informationAcute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis
Acute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis This guideline, developed by Larry Simmons, MD, in collaboration with the ANGELS team, on October 3, 2013, is a significantly
More informationManagement of URTI s in Children
Management of URTI s in Children Robin J Green PhD Antibiotics - Dilemmas for General Practitioners Antibiotic overuse = Resistance Delay in antibiotic use = Mortality Patient expectation Employer expectation
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationSynflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed
Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE
More informationACUTE PAEDIATRIC EAR PRESENTATIONS PROF IAIN BRUCE PAEDIATRIC OTOLARYNGOLOGIST & ADULT OTOLOGIST
www.manchesterchildrensent.com ACUTE PAEDIATRIC EAR PRESENTATIONS PROF IAIN BRUCE PAEDIATRIC OTOLARYNGOLOGIST & ADULT OTOLOGIST A CHILD WITH EARACHE UNCOMPLICATED AOM ACUTE OTITIS MEDIA Acute otitis media
More informationPOLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: July 2013 Approved by: The Drugs & Therapeutics Committee Date: April 2016 Implementation
More informationfor the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland
2012 Antigen Review for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand Ministry
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationRespiratory System Virology
Respiratory System Virology Common Cold: Rhinitis. A benign self limited syndrome caused by several families of viruses. The most frequent acute illness in industrialized world. Mild URT illness involving:
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationPneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) Ph.Eur., 13-valent PREVENAR 13
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) Ph.Eur., 13-valent PREVENAR 13 1. NAME OF THE MEDICINAL PRODUCT
More informationMalik Sallam. Ola AL-juneidi. Ammar Ramadan. 0 P a g e
1 Malik Sallam Ola AL-juneidi Ammar Ramadan 0 P a g e Today's lecture will be about viral upper respiratory tract infections. Those include: common cold, sinusitis, otitis, etc. Infections in the upper
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) 2. QUALITATIVE AND
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME SYNFLORIX pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)
More informationUpper Respiratory Tract Infections / 42
Upper Respiratory Tract Infections 1 Upper Respiratory Tract Infections Acute tonsillitispharyngitis Acute otitis media Acute sinusitis Common cold Acute laryngitis Otitis externa Mastoiditis Acute apiglottis
More informationPr Robert Cohen CHI Créteil France
EFFECT OF VACCINATION ON ANTIMICROBIAL RESISTANCE : THE EXAMPLE OF THE IMPACT OF PCVS ON ANTIBIOTIC RESISTANCE Pr Robert Cohen CHI Créteil France 1 DISCLOSURES I have received during the las 3 years honorarium
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE
More informationPneumoccocal vaccines in the elderly (conjugated vs polysaccharides)
Aging and Immunity II Campus Novartis, Siena April 24, 2012 Pneumoccocal vaccines in the elderly (conjugated vs polysaccharides) Paolo Bonanni Department of Public Health University of Florence, Italy
More informationRespiratory tract infections. Krzysztof Buczkowski
Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria
More information14/10/16. Background. Streptococcus pneumoniae (Sp) is an important cause for these diseases
Estimates of the potential public health impact and cost-effectiveness of adopting pneumococcal vaccination in the routine immunization programme in African GAVI countries: a modelling study C. Sauboin
More informationThe importance of considering BACTERIAL LOAD in OTITIS MEDIA research
The importance of considering BACTERIAL LOAD in OTITIS MEDIA research Heidi Smith-Vaughan, Robyn Marsh, Michael Binks, Mirjam Kaestli, Peter S Morris, Amanda J Leach OM in Indigenous children OM is endemic
More informationRespiratory Diseases and Disorders
Chapter 9 Respiratory Diseases and Disorders Anatomy and Physiology Chest, lungs, and conducting airways Two parts: Upper respiratory system consists of nose, mouth, sinuses, pharynx, and larynx Lower
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationUpper Respiratory tract Infec1on. Gassem Gohal FAAP FRCPC
Upper Respiratory tract Infec1on Gassem Gohal FAAP FRCPC Anatomy Contents Sinusitis Common Cold Otitis media pharyngitis Epiglottitis Croup Trachitis Sinuses Sinus development Born with ME ( Maxillary,
More informationRisk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology
More informationRisk and Prevention of Pneumococcal Disease in Adults
Risk and Prevention of Pneumococcal Disease in Adults Athena 2015. International Conference Antoni Torres. University of Barcelona 1 Pneumococcal pneumonia represents the majority of pneumococcal disease*
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUpper Respiratory Tract Infections
Upper Respiratory Tract Infections OTITIS MEDIA Otitis media is an inflammation of the middle ear. There are more than 709 million cases of otitis media worldwide each year; half of these cases occur in
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX Pneumococcal Polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) Protein D Conjugate Vaccine, adsorbed
More informationAssociation of Clinical Signs and Symptoms with Pneumococcal Acute Otitis Media by Serotype Implications for Vaccine Effect
MAJOR ARTICLE Association of Clinical Signs and Symptoms with Pneumococcal Acute Otitis Media by Serotype Implications for Vaccine Effect Arto A. I. Palmu, 1,2 Jukka T. Jokinen, 1 Tarja Kaijalainen, 1
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationAuthor's response to reviews
Author's response to reviews Title: Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination Authors: Grant
More informationPneumococcal pneumonia
Pneumococcal pneumonia Wei Shen Lim Consultant Respiratory Physician & Honorary Professor of Medicine Nottingham University Hospitals NHS Trust University of Nottingham Declarations of interest Unrestricted
More informationHow It Spreads Symptoms Can Include Complications
OUR BEST SHOT: The Importance of Vaccines for Older Adults VACCINES QUICK GUIDE TO VACCINATION FOR ADULTS AGES 60+ Vaccines are an important step in protecting your health and the health of your family.
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Acute Otitis Media. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationPRODUCT MONOGRAPH SYNFLORIX
PRODUCT MONOGRAPH SYNFLORIX Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed Suspension for injection Active immunizing
More informationPatient & Family Guide. Pneumovax 23. (Pneumococcal Vaccine Polyvalent) and Kidney Disease.
Patient & Family Guide 2018 Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease www.nshealth.ca Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease What is Pneumovax 23? Pneumovax
More informationImpact of vaccination on epidemiology in adults
Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction
More informationpneumonia 2015;6:48 56
pneumonia 2015 Aug 21;6:48 56 pneumonia Brief Report Anne B Chang a,b, Heidi Smith-Vaughan a,c, Theo P Sloots f, Patricia C Valery a, David Whiley f, Jemima Beissbarth a, Paul J Torzillo d,e a Menzies
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment McCormick D P, Chonmaitree T, Pittman C, Saeed K, Friedman N R, Uchida T, Baldwin
More informationJimmy's Got Cooties! Common Childhood Infections and How Best to Treat Them
Jimmy's Got Cooties! Common Childhood Infections and How Best to Treat Them Objectives:! Recognize and manage several infections commonly seen in Pediatric practice! Discuss best practices and current
More informationClinical Practice Guideline: Tonsillectomy in Children, Baugh et al Otolaryngology Head and Neck Surgery, 2011 J and: 144 (1 supplement) S1 30.
Pediatric ENT Guidelines Jane Cooper, FNP, CORLN References: Clinical Practice Guideline: Tympanostomy tubes in children, Rosenfeld et al., American Academy of Otolaryngology Head and Neck Surgery Foundation
More informationPneumococcal Vaccine in Children: current situation
Pneumococcal Vaccine in Children: current situation LAU Yu Lung Chair Professor of Paediatrics Doris Zimmern Professor in Community Child Health LKS Faculty of Medicine, The University of Hong Kong Chairman
More informationSurveillance of invasive pneumococcal infection in Belgium
Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility
More informationSubspecialty Rotation: Otolaryngology
Subspecialty Rotation: Otolaryngology Faculty: Evelyn Kluka, M.D. GOAL: Hearing Loss. Understand the morbidity of hearing loss, intervention strategies, and the pediatrician's and other specialists' roles
More informationSYNFLORIX PRODUCT INFORMATION Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed
SYNFLORIX PRODUCT INFORMATION Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed NAME OF THE MEDICINE Synflorix Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed DESCRIPTION
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDefinitions of Otitis Media
Definitions of Otitis Media T H I S T E A C H I N G P R E S E N T A T I O N F O R T H E I S O M W E B S I T E H A S B E E N P R E P A R E D B Y T A L M A R O M, M D A N D S H A R O N O V N A T T A M I
More informationWould a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
More informationReport of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland,
Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, 2011-2013 1. Background Streptococcus pneumoniae is a major cause of life-threatening infections
More informationBIOS222 TUTORIAL ACTIVITY SESSION 1
BIOS222 TUTORIAL ACTIVITY SESSION 1 Instructions: The Tutorial activities are designed to help you practice the concepts learned in the lecture. Read the following case studies and answer the questions
More information- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) 2. QUALITATIVE AND
More informationRESPIRATORY TRACT INFECTIONS. CLS 212: Medical Microbiology Zeina Alkudmani
RESPIRATORY TRACT INFECTIONS CLS 212: Medical Microbiology Zeina Alkudmani Lower Respiratory Tract Upper Respiratory Tract Anatomy of the Respiratory System Nasopharynx Oropharynx Respiratory Tract Infections
More informationCommunicable Disease. Introduction
Communicable Disease HIGHLIGHTS Seniors have the highest incidence rates of tuberculosis compared to other age groups. The incidence rates for TB have been higher among Peel seniors compared to Ontario
More information...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7
...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on
More informationPneumococcal Vaccines The Impact Of Conjugate Vaccine
Pneumococcal Vaccines The Impact Of Conjugate Vaccine 1 / 5 2 / 5 3 / 5 Pneumococcal Vaccines The Impact Of Pneumococcal vaccine. The pneumococcal vaccine protects against serious and potentially fatal
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00869.x Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy I. Serrano, M. Ramirez, the Portuguese Surveillance
More informationFaculty Disclosure. Stephen I. Pelton, MD. Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Stephen I. Pelton, MD Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest. Advances in the management of fever in infants 0 to 3 and
More informationVaccines. Robert Read University of Southampton University Hospital Southampton
Vaccines Robert Read University of Southampton University Hospital Southampton Disclosures Non personal, non specific; Novartis-GSK Member, JCVI Editor in Chief, Journal of Infection, and Current Opinion
More informationThe Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 To provide guidelines for administering immunizations. PURPOSE POLICY Immunizations are to be administered to all patients in accordance with the North Carolina Immunization Regulations and
More informationPOLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: Date: July 2018 The Drugs & Therapeutics Committee Implementation
More informationAssessment of Hearing Level after Resolution of Acute Otitis Media. Ali Maeed Al-shehri*
Bahrain Medical Bulletin, Vol. 32, No. 4, December 2010 Assessment of Hearing Level after Resolution of Acute Otitis Media Ali Maeed Al-shehri* Background: Acute otitis media is a very common global bacterial
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar suspension for injection Pneumococcal saccharide conjugated vaccine, adsorbed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationAssessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University
Assessing public health impact through vaccine probe analyses Robert F. Breiman Emory Global Health Institute Emory University State of understanding the relative role of pathogens in major disease syndromes
More information